000			04195nam a22003615i 4500
999			_c77851 _d77851 _x1
001			77851
003			ES-MaUEC
005			20230202102334.0
007			cr nn 008mamaa
008			141201s2014 xxu| s |||| 0|eng d
020			_a9781493913046
024	7		_a10.1007/978-1-4939-1304-6 _2doi
040			_dES-MaUEC
050		4	_aRS187 _b.S365 2014
100	1		_aSchmidt, Stephan. _eeditor literario _986811 _0Local
245	1	0	_aApplied Pharmacometrics _cedited by Stephan Schmidt, Hartmut Derendorf.
260			_aNew York _bSpringer International Publishing _c2014
300			_a1 recurso en línea (XIII, 565 p.) _b161 ilustraciones, 94 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aAAPS Advances in the Pharmaceutical Sciences Series _x2210-7371 _v14
505	0		_a1 Introduction to Pharmacometrics and Quantitative Pharmacology with an Emphasis on Physiologically Based Pharmacokinetics -- 2 Personalized Medicine â€{u026E}tegrating Individual Exposure and Response Information at the Bedside -- 3 Pharmacometrics in Pediatrics -- 4 Pharmacometrics in Chronic Kidney Disease -- 5 Drug-Disease Model-Based Development of Therapeutic Agents for Treatment of Diabetes -- 6 Applied Pharmacometrics in the Obese Population -- 7 Pharmacometrics in Cardiovascular Safety -- 8 Pharmacometrics in Bacterial Infections -- 9 Pharmacometrics in Viral Infections -- 10 Applied Antifungal Pharmacometrics: Fluconazole and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis -- 11 Pharmacometrics and Tuberculosis -- 12 Pharmacometrics in Pulmonary Diseases -- 13 State-of-the-Art Pharmacometric Models in Osteoporosis -- 14 Pharmacometrics in Psychiatric Diseases -- 15 Clinical Trial Simulation in Alzheimerâ€{u3804}isease -- 16 Pharmacometric Applications in Inflammation -- 17 Pharmacometrics in Dermatology -- 18 Pharmacometrics in Pain Management -- 19 Pharmacometrics of Hyperlipidemia.
520			_aThis comprehensive volume provides an update on the current state of pharmacometrics in drug development. It consists of nineteen chapters all written by leading scientists from the pharmaceutical industry, regulatory agencies and academia. After an introduction of the basic pharmacokinetic and pharmacodynamic concepts of pharmacometrics in drug development, the book presents numerous examples of specific applications that utilize pharmacometrics with modeling and simulations over a variety of therapeutic areas, including pediatrics, diabetes, obesity, infections, psychiatrics, Alzheimerâ€{u3824}isease, and dermatology, among others. The examples illustrate how results from all phases of drug development can be integrated in a more timely and cost-effective process. Applying pharmacometric decision tools during drug development can allow objective, data-based decision making. At the same time, the process can identify redundant or unnecessary experiments as well as some costly clinical trials that can be avoided. In addition to cost saving by expedited development of successful drug candidates, pharmacometrics has an important economic impact in drug product selection.Â{u056E}successful drug candidates can be identified early and discontinued without expending efforts required for additional studies and allocating limited resources. Hence, pharmacometric modeling and simulation has become a powerful tool to bring new and better medications to the patient at a faster pace and with greater probability of success.
650		7	_2embne _9149216 _aMateria médica
700	1		_aDerendorf, Hartmut _eeditor literario _986812 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4939-1304-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12843301 _b10-10-17 _c23-02-15
942			_2lcc _cLE
945			_aRS187 .S365 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11556213 _z06-04-17
988			_aEBSPRINGER
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _gxxu _h0